Finance

Beta
Lists
8AP:FRA
Agios Pharmaceuticals Inc
€24.60
-0.81%
(-0.20) 1D
Jun 12, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 8AP...
Open
€24.60
High
€24.60
Low
€24.60
Mkt. cap
1.75B
Avg. vol.
6.00
Volume
0.00
52-wk high
€38.80
52-wk low
€19.70
No. of employees
540
Open
€24.60
High
€24.60
Low
€24.60
Mkt. cap
1.75B
Avg. vol.
6.00
Volume
0.00
52-wk high
€38.80
52-wk low
€19.70
No. of employees
540
News stories
From sources across the web
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
SectorBiotechnology
Websiteagios.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
12.46M
12.88M
19.97M
20.75M
Cost of goods sold
93.64M
88.48M
89.94M
82.47M
Cost of revenue
93.64M
88.48M
89.94M
82.47M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45.87M
41.27M
51.61M
48.30M
Operating expense
45.87M
41.27M
51.61M
48.30M
Total operating expenses
139.51M
129.75M
141.54M
130.77M
Operating income
-127.06M
-116.87M
-121.58M
-110.02M
Other non operating income
523.00K
67.00K
113.00K
119.00K
EBT including unusual items
-112.02M
-103.43M
-109.06M
-99.11M
EBT excluding unusual items
-112.02M
-103.43M
-109.06M
-99.11M
Income tax expense
-
-
-1.02M
-
Effective tax rate
-
-
0.93%
-
Other operating expenses
-
-
-
-
Net income
-112.02M
-103.43M
-108.04M
-99.11M
Net profit margin
-899.40%
-803.05%
-541.09%
-477.74%
Earnings per share
-1.93
-1.78
-1.85
-1.69
Interest and investment income
14.51M
13.37M
12.41M
10.80M
Interest expense
-
-
-
-
Net interest expenses
14.51M
13.37M
12.41M
10.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-125.80M
-115.50M
-120.31M
-108.66M
Gain or loss from assets sale
5.00K
299.00K
-299.00K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer